Navigation Links
Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes
Date:8/6/2014

DUBLIN, Aug. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of exchangeable senior notes due 2021 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  In connection with the offering, the Issuer expects to grant the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of such notes solely to cover over-allotments, if any.

The notes will be exchangeable under certain circumstances for cash, ordinary shares of Jazz Pharmaceuticals plc ("ordinary shares"), or a combination thereof, based on an exchange rate to be determined.  The Issuer's obligations under the notes will be fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc.  The initial exchange rate, interest rate and certain other terms of the notes will be determined by negotiations between Jazz Pharmaceuticals and the initial purchasers.

Jazz Pharmaceuticals intends to use a portion of the net proceeds from the proposed offering to repay outstanding borrowings under its revolving credit facility and to use the remainder of the net proceeds for general corporate purposes, including potential business development activities. 

The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act.  None of the notes, the guarantee or the ordinary shares issuable upon exchange of the notes, if any, has been registered under the Securities Act or the securities laws of any other jurisdiction, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. 

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any notes, the guarantee or ordinary shares, nor shall there be any sale of notes, the guarantee or ordinary shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.  Any offer, if at all, will be made only pursuant to Rule 144A under the Securities Act.

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz® (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide).

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, all statements related to the proposed offering, including the expected principal amount and terms of the notes, and the expected use of the net proceeds from the proposed offering.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions, whether the Issuer will offer the notes or whether Jazz Pharmaceuticals plc and the Issuer will be able to consummate the proposed offering at the anticipated size and on the anticipated terms, or at all, and the satisfaction of closing conditions related to the proposed offering; Jazz Pharmaceuticals' ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on Jazz Pharmaceuticals' ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations.  These and other risks and uncertainties relating to Jazz Pharmaceuticals and its business can be found under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and future filings and reports by Jazz Pharmaceuticals plc.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations. 


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
2. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
3. Jazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.
4. Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance
5. Cumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results
6. Avanir Pharmaceuticals to Participate in Two Conferences in August
7. Heritage Pharmaceuticals Inc. Signs Exclusive Development Supply & Distribution Agreement with Dexcel Ltd.
8. Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
9. Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13
10. Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report with New Material Information
11. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology:
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
Breaking Medicine News(10 mins):